Drug
mefloquine plus artesunate
mefloquine plus artesunate is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_3
1
33%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 3Large-scale testing
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (50.0%)
Phase 31 (50.0%)
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_3
Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients
NCT00403260
completedphase_1
Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease
NCT01319448
completed
Efficacy and Effectiveness of Combined Therapy for Uncomplicated Malaria Treatment in Peru
NCT00164216
Clinical Trials (3)
Showing 3 of 3 trials
NCT00403260Phase 3
Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients
NCT01319448Phase 1
Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease
NCT00164216
Efficacy and Effectiveness of Combined Therapy for Uncomplicated Malaria Treatment in Peru
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3